CoChat

Short-term combined treatment with exenatide and metformin for overweight/obese women with polycystic ovary syndrome

Open access
Ma, Rui-Lin, Deng, Yan, Wang, Yan-Fang, Zhu, Shi-Yang, Ding, Xue-Song, Sun, Ai-Jun · 2021 · Chinese Medical Journal
Cited by 59

The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.

Abstract

Background: Obesity and insulin resistance (IR) are common features of polycystic ovary syndrome (PCOS). Metformin (MET) increases insulin sensitivity, but it is associated with unsatisfactory weight loss. The glucagon-like peptide-1 receptor agonist exenatide has been shown to reduce weight and IR in patients with diabetes. This study aimed to explore the therapeutic effects of exenatide once-weekly (QW) combined with MET on body weight, as well as metabolic and endocrinological parameters in overweight/obese women with PCOS. Methods: Fifty overweight/obese women with PCOS diagnosed via the Rotterdam criteria were randomized to one of two treatment groups: MET (500 mg three times a day [TID]) or combination treatment (COM) (MET 500 mg TID, exenatide 2 mg QW) for 12 weeks. The primary outcomes were anthropometric changes associated with obesity, and the secondary outcomes included changes in reproductive hormone levels, glucose and lipid metabolism, and C-reactive protein. Results: Forty (80%) patients completed the study. COM therapy was superior to MET monotherapy in reducing weight (P = 0.045), body mass index (BMI) (P = 0.041), and waist circumference (P = 0.023). Patients in the COM group on an average lost 3.8 ± 2.4 kg compared with 2.1 ± 3.0 kg in the MET group. In the COM group, BMI and waist circumference decreased by 1.4 ± 0.87 kg/m 2 and 4.63 ± 4.42 cm compared with 0.77 ± 1.17 kg/m 2 and 1.72 ± 3.07 cm in the MET group, respectively. Moreover, levels of fasting glucose, oral glucose tolerance test (OGTT) 2-h glucose, and OGTT 2-h insulin were significantly lower with COM therapy than with MET (P < 0.050). Mild and moderate gastrointestinal reactions were the most common adverse events in both groups. Conclusions: COM therapy was more effective than MET alone in reducing body weight, BMI, and waist circumference, and improving insulin sensitivity in overweight/obese women with PCOS, with acceptable short-term side effects. Trial registration: ClinicalTrials.gov, NCT04029272. https://clinicaltrials.gov/ct2/show/NCT04029272

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/cm9.0000000000001712

Cites

14 of 14 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 14 references

Research works printed but not linked: 14

  1. Wang, 2016, Comparison of drospirenone- with cyproterone acetate-containing oral contraceptives, combined with metformin and lifestyle modifications in women with polycystic ovary syndrome and metabolic disorders: a prospective randomized control trial, Chin Med J (Engl), 129, 883, 10.4103/0366-6999.179783 · DOI
  2. Dumitrescu, 2015, Metformin-clinical pharmacology in PCOs, J Med Life, 8, 187
  3. Sfairopoulos, 2018, Clinical pharmacology of glucagon-like peptide-1 receptor agonists, Hormones (Athens), 17, 333, 10.1007/s42000-018-0038-0 · DOI
  4. Htike, 2017, Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: a systematic review and mixed-treatment comparison analysis, Diabetes Obes Metab, 19, 524, 10.1111/dom.12849 · DOI · Paper page
  5. Sever, 2014, Short-term combined treatment with liraglutide and metformin leads to significant weight loss in obese women with polycystic ovary syndrome and previous poor response to metformin, Eur J Endocrinol, 170, 451, 10.1530/EJE-13-0797 · DOI · Paper page
  6. Grossman, 2014, Pathophysiological and pharmacological rationale for the use of exenatide once weekly in patients with type 2 diabetes, Adv Ther, 31, 247, 10.1007/s12325-014-0101-4 · DOI
  7. Wysham, 2018, Efficacy and tolerability of the new autoinjected suspension of exenatide once weekly versus exenatide twice daily in patients with type 2 diabetes, Diabetes Obes Metab, 20, 165, 10.1111/dom.13056 · DOI
  8. Zheng, 2017, Short term monotherapy with exenatide is superior to metformin in weight loss, improving insulin resistance and inflammation in Chinese overweight/obese PCOS women, Obes Med, 7, 15, 10.1016/j.obmed.2017.06.003 · DOI
  9. Liu, 2017, Efficacy of exenatide on weight loss, metabolic parameters and pregnancy in overweight/obese polycystic ovary syndrome, Clin Endocrinol (Oxf), 87, 767, 10.1111/cen.13454 · DOI · Paper page
  10. Mhao, 2016, A comparative study to illustrate the benefits of using ethinyl estradiol-cyproterone acetate over metformin in patients with polycystic ovarian syndrome, Diabetes Metab Syndr, 10, S95, 10.1016/j.dsx.2015.10.001 · DOI · Paper page
  11. Glintborg, 2017, Effect of oral contraceptives and/or metformin on GLP-1 secretion and reactive hypoglycaemia in polycystic ovary syndrome, Endocr Connect, 6, 267, 10.1530/EC-17-0034 · DOI · Paper page
  12. Su, 2016, Exenatide in obese or overweight patients without diabetes: a systematic review and meta-analyses of randomized controlled trials, Int J Cardiol, 219, 293, 10.1016/j.ijcard.2016.06.028 · DOI
  13. Prelević, 1990, Effects of a low-dose estrogen-antiandrogen combination (Diane-35) on lipid and carbohydrate metabolism in patients with polycystic ovary syndrome, Gynecol Endocrinol, 4, 157, 10.3109/09513599009009803 · DOI
  14. Villaseca, 2004, Ethinylestradiol/cyproterone acetate in polycystic ovary syndrome: lipid and carbohydrate changes, Eur J Contracept Reprod Health Care, 9, 155, 10.1080/13625180400007751 · DOI

Cited by

See all 59

Metadata

Authors
Ma, R.-L., Deng, Y., Wang, Y.-F., Zhu, S.-Y., Ding, X.-S., & Sun, A.-J.
Venue
Chinese Medical Journal
Published
2021-11-03
Volume
134
Issue
23
Pages
2882-2889
ISSN
  • 0366-6999 (ISSN-L)
  • 2542-5641
OpenAlex
W3209468918
Cited by
59
References
14
FWCI
5.11
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Short-term combined treatment with exenatide and metformin for overweight/obese women with polycystic ovary syndrome. https://app.cochat.ai/papers/10.1097/cm9.0000000000001712
The paper
Ma, R.-L., Deng, Y., Wang, Y.-F., Zhu, S.-Y., Ding, X.-S., & Sun, A.-J. (2021). Short-term combined treatment with exenatide and metformin for overweight/obese women with polycystic ovary syndrome. Chinese Medical Journal. https://doi.org/10.1097/cm9.0000000000001712

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.